<DOC>
	<DOC>NCT01987453</DOC>
	<brief_summary>The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV) in participants with chronic genotype 1 hepatitis C virus (HCV) infection who have participated in a prior Gilead-sponsored HCV treatment study, and who did not achieve sustained virologic response (SVR24), defined as HCV RNA &lt; lower limit of quantification (LLOQ) 24 weeks after last dose of study drug (SVR24).</brief_summary>
	<brief_title>Ledipasvir/Sofosbuvir Fixed-Dose Combination Â± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study</brief_title>
	<detailed_description />
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Key Willing and able to provide written informed consent Infection with HCV genotype 1 HCV RNA &gt; LLOQ at screening Participation in a prior Gileadsponsored study Screening laboratory values within defined thresholds Use of two effective contraception methods if female of childbearing potential or sexually active male Must be of generally good health, with the exception of chronic HCV infection, as determined by the Investigator Must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments Key Pregnant or nursing female or male with pregnant female partner Coinfection with HIV or hepatitis B virus (HBV) Current or prior history of clinical hepatic decompensation (Groups 1 and 2 only) Hepatocellular carcinoma (HCC) History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>genotype 1</keyword>
</DOC>